Back to Search
Start Over
Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma
- Source :
- International Journal of Hematology. 90:635-642
- Publication Year :
- 2009
- Publisher :
- Springer Science and Business Media LLC, 2009.
-
Abstract
- The efficacy and safety of high-dose chemotherapy with tandem autologous peripheral blood stem cell transplantation (auto-PBSCT) were evaluated in a multicenter clinical study of patients with advanced multiple myeloma. Eligible patients (n = 40) were consecutively enrolled in the phase I/II study and received 2-4 cycles of vincristine-adriamycin-dexamethasone regimen. The responding patients underwent PBSC harvesting following high-dose cyclophosphamide and filgrastim administration. The first auto-PBSCT (n = 32) following high-dose melphalan (200 mg/m(2)) was performed within 2 months of PBSC harvesting; the second auto-PBSCT (n = 28) was scheduled 3-6 months later. Treatment-related mortality was 2.5% (n = 1) throughout the protocol. Grade 4 nonhematologic toxicity occurred in 12.5 and 14.3% of the first and second auto-PBSCT patients, respectively. All but one patient (who died) achieved hematopoietic recovery. For the 28 patients completing the second auto-PBSCT, the results were favorable with a response rate of 65% (complete response rate = 27.5%, n = 11); the five-year progression-free survival and overall survival were 20.3 and 66.5%, respectively. In conclusion, high-dose chemotherapy with tandem auto-PBSCT is feasible and safe with a favorable response rate in treating advanced multiple myeloma in Japan.
- Subjects :
- Melphalan
medicine.medical_specialty
Cyclophosphamide
medicine.medical_treatment
Filgrastim
Transplantation, Autologous
Dexamethasone
Antineoplastic Combined Chemotherapy Protocols
Humans
Medicine
Survival rate
Multiple myeloma
Peripheral Blood Stem Cell Transplantation
Chemotherapy
business.industry
Hematology
medicine.disease
Combined Modality Therapy
Surgery
Survival Rate
Transplantation
Regimen
Treatment Outcome
Doxorubicin
Vincristine
Multiple Myeloma
business
medicine.drug
Subjects
Details
- ISSN :
- 18653774 and 09255710
- Volume :
- 90
- Database :
- OpenAIRE
- Journal :
- International Journal of Hematology
- Accession number :
- edsair.doi.dedup.....cddaf2130977d83da4807865ff1d3f20